Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: Adv Drug Deliv Rev. 2023 Mar 6;196:114771. doi: 10.1016/j.addr.2023.114771

Figure 3:

Figure 3:

Matrix stiffness and chemotherapy regulate stem cell marker expression in HepG2 cells. (A) Quantification by flow cytometric analysis of putative cancer stem cell markers CD133, c-kit, CD44 and CXCR-4 in HepG2 cells cultured for 5 days on soft (1 kPa) or stiff (12 kPa) supports. Cells were either left untreated (black) or treated for 24 hours with cisplatin (white). Results are representative of three independent experiments. (B) Real-time quantitative PCR analysis of octamer-4 (OCT4) (left panel) and NANOG (right panel) expression in HepG2 cells cultured for 5-days on soft (1 kPa) or stiff (12 kPa) supports. Cells were either left untreated (black) or treated for 24 hours with cisplatin (white). Expression is relative to the 18S housekeeping gene. In each case, error bars represent SEM, *P < 0.05, **P < 0.01, and ***P < 0.001. Adapted with permission from Schrader et al. 93.